1. Scrip
  2. >>New Products

Aduhelm Approval Boosts Other Alzheimer’s Drug Developers

Even Companies Not Focused On Clearing Amyloid Benefitted

 
• By Mandy Jackson

Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.

Alzheimer's and dementia research, a brain scan in multi well tray used for research experiments in laboratory
Investment in Alzheimer's R&D should get a boost from Aduhelm's approval • Source: Alamy

It was a great day for Alzheimer’s drug developers, regardless of the type of therapies in their pipelines, on 7 June when the US Food and Drug Administration granted accelerated approval for Biogen, Inc./Eisai Co., Ltd.’s amyloid-clearing antibody Aduhelm (aducanumab). The closely watched decision was hailed by patient advocates, research groups and investors as an advance for the Alzheimer’s field that will boost investment in drugs for the disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.